Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.94 |
| ▸ | RAB9A | P51151 | 1/20 | 0.94 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58442 | 0.97 | MEN1 (1.00) | MEN1KMT2ARAB9AASIC3ALDH1A1 | |
| Bromide SCHEMBL10753629 | 0.94 | MEN1 (0.94) | MEN1KMT2ARAB9AASIC3ALDH1A1 | |
| SCHEMBL5945940 | 0.94 | MEN1 (0.94) | MEN1KMT2ARAB9AASIC3ALDH1A1 | |
| SCHEMBL16077969 | 0.94 | MEN1 (0.94) | MEN1KMT2ARAB9AASIC3ALDH1A1 | |
| SCHEMBL18732402 | 0.92 | MEN1 (0.89) | MEN1KMT2ARAB9AASIC3ALDH1A1 | |
| Bromide SCHEMBL10757159 | 0.92 | MEN1 (0.89) | MEN1KMT2ARAB9AASIC3ALDH1A1 | |
| SCHEMBL3631391 | 0.92 | MEN1 (0.89) | MEN1KMT2ARAB9AASIC3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4387943 | 0.89 | KMT2A (0.84) | MEN1KMT2ARAB9AASIC3ALDH1A1 | |
| SCHEMBL23869334 | 0.87 | MEN1 (0.80) | MEN1KMT2ARAB9AASIC3ALDH1A1 | |
| SCHEMBL28476283 | 0.87 | MEN1 (0.80) | MEN1KMT2ARAB9AASIC3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632827-B2 | Antitumor agents; cytotoxic toward cells in vivo, in vitro | THE UNIVERSITY OF HONG KONG (HK) | 2009-12-15 | — | — | US | claimed |
| US-20080166429-A1 | ANTI-CANCER PHOSPHINE CONTAINING [AuIIIm(CNC)mL]n+ COMPLEXES AND DERIVATIVES THEREOF AND METHODS FOR TREATING CANCER USING SUCH COMPOSITIONS | THE UNIVERSITY OF HONG KONG | 2008-07-10 | — | — | US | claimed |
| US-7632827-B2 | Antitumor agents; cytotoxic toward cells in vivo, in vitro | THE UNIVERSITY OF HONG KONG (HK) | 2009-12-15 | — | — | US | disclosed |
| US-20080166429-A1 | ANTI-CANCER PHOSPHINE CONTAINING [AuIIIm(CNC)mL]n+ COMPLEXES AND DERIVATIVES THEREOF AND METHODS FOR TREATING CANCER USING SUCH COMPOSITIONS | THE UNIVERSITY OF HONG KONG | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166429-A1 | ANTI-CANCER PHOSPHINE CONTAINING [AuIIIm(CNC)mL]n+ COMPLEXES AND DERIVATIVES THEREOF AND METHODS FOR TREATING CANCER USING SUCH COMPOSITIONS | NCL, NPM1, MCL1 | MEN1 1660/4885KMT2A 2158/4885RAB9A 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.